ReviewAdvances in chronic kidney disease2013
Applications of nanoparticles in the detection and treatment of kidney diseases.
Review in Advances in chronic kidney disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Nephroprotective effects of visnagin through modulation of macrophage polarization, oxidative stress, inflammation and apoptosis in renal I/R injury.Open medicine (Warsaw, Poland) · 2026Article
- Review
- The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer.Drug delivery · 2022Article
- 2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis.Antioxidants (Basel, Switzerland) · 2022Article
- Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.Signal transduction and targeted therapy · 2022Review
- Sensitivity and Selectivity Analysis of Fluorescent Probes for Hydrogen Sulfide Detection.Chemistry, an Asian journal · 2022Article
- Pharmaceutical nanotechnology: from the bench to the market.Future journal of pharmaceutical sciences · 2022Review
- The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases.International journal of molecular sciences · 2021Review
- Magnetic Iron Oxide Nanoparticles for Biomedical Applications.Current opinion in biomedical engineering · 2021Article
- PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT.Scientific reports · 2021Article
- Recent advances in nanotherapeutics for the treatment and prevention of acute kidney injury.Asian journal of pharmaceutical sciences · 2021Review
- A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease.Bioactive materials · 2020Review
- Light-Emitting Agents for Noninvasive Assessment of Kidney Function.ChemistryOpen · 2017Review
- Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle.Biomaterials · 2017Article
- Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.Biomaterials science · 2017Article
- pH-Responsive Mesoporous Silica and Carbon Nanoparticles for Drug Delivery.Bioengineering (Basel, Switzerland) · 2017Review
- Future of the Renal Biopsy: Time to Change the Conventional Modality Using Nanotechnology.International journal of biomedical imaging · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nanoparticles have emerged in the medical field as a technology well suited for the diagnosis and treatment of various disease states. They have been heralded as efficacious in terms of improved therapeutic efficacy and reduction of treatment side effects in some cases. Various nanomaterials have been developed that can be tagged with targeting moieties as well as with drug delivery and imaging capability or a combination of both as a theranostic agent. These nanomaterials have been investigated for treatment and detection of various pathological conditions. The emphasis of this review is to demonstrate current research and clinical applications for nanoparticles in the diagnosis and treatment of kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.